The Role of β-Catenin and c-Myc Dysregulation in Acute Myeloid Leukemia: A Study of Egyptian Patients

Acute Myeloid Leukemia (AML) is a treatable but aggressive hematologic malignancy attributed to both genetic and epigenetic mutations in hematopoietic stem cells (HSCs). The disease is highly genetically heterogeneous with mutations in important genes like FLT3, NPM1 and TP53. Wnt/β-catenin dysregulated signaling pathways3839 are implicated in the majority of AML pathogenesis as they promote tumor progression and cancer stem cell-like properties also inhibit normal haemopoiesis. One of the crucial mediators of Wnt pathway, β-catenin plays a pivotal role in regulating HSC self-renewal, differentiation, and expression of oncogenes such as c-Myc. Dysregulation of c-Myc, often observed in AML, is associated with poor prognosis and chemoresistance.The present study aimed to investigate the expression of β-catenin and c-Myc mRNA in Egyptian patients with acute myeloid leukemia (AML), and its relationship to clinical parameters as well as AML subtypes. Clinical characteristics of AML patients were analyzed in our cohort relative to healthy controls, we demonstrated that kidney and liver dysfunction were frequent manifestations among AML patients which showed significantly higher serum creatinine, urea, ALT and AST levels compared with healthy individuals.Plasma β-catenin levels were significantly lower in AML patients, particularly in the M4/M5 subtypes characterized by monocytic differentiation. In contrast, no significant difference in β-catenin levels was observed between M0-M2 subtypes and controls. Age and FAB subtypes influenced β-catenin levels, with lower levels common in middle-aged patients (30–45 years) and the M5 subtype, while higher levels were associated with younger patients (18–30 years) and the M1 subtype.Expression of c-Myc mRNA did not differ significantly between overall AML patients and controls. However, subgroup analysis revealed substantially lower c-Myc expression in M4/M5 subtypes compared to M0-M2 subtypes and controls

Authors

Institutions

Publication Details

Journal
Future Perspectives of Medical Pharmaceutical and Environmental Biotechnology
Published
2024-10-01
DOI
https://doi.org/10.21608/fpmpeb.2024.393422
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Role of β-Catenin and c-Myc Dysregulation in Acute Myeloid Leukemia: A Study of Egyptian Patients

Howaida A. Nounou, S. Eltabakh, Ahmed Darwish, N. Rasheed et al.
Future Perspectives of Medical Pharmaceutical and Environmental Biotechnology
HER2/EGFR in Cancer Research
article

The Role of β-Catenin and c-Myc Dysregulation in Acute Myeloid Leukemia: A Study of Egyptian Patients

Howaida A. Nounou, S. Eltabakh, Ahmed Darwish, N. Rasheed, Nahla A M Hamed
article en

Abstract

Acute Myeloid Leukemia (AML) is a treatable but aggressive hematologic malignancy attributed to both genetic and epigenetic mutations in hematopoietic stem cells (HSCs). The disease is highly genetically heterogeneous with mutations in important genes like FLT3, NPM1 and TP53. Wnt/β-catenin dysregulated signaling pathways3839 are implicated in the majority of AML pathogenesis as they promote tumor progression and cancer stem cell-like properties also inhibit normal haemopoiesis. One of the crucial mediators of Wnt pathway, β-catenin plays a pivotal role in regulating HSC self-renewal, differentiation, and expression of oncogenes such as c-Myc. Dysregulation of c-Myc, often observed in AML, is associated with poor prognosis and chemoresistance.The present study aimed to investigate the expression of β-catenin and c-Myc mRNA in Egyptian patients with acute myeloid leukemia (AML), and its relationship to clinical parameters as well as AML subtypes. Clinical characteristics of AML patients were analyzed in our cohort relative to healthy controls, we demonstrated that kidney and liver dysfunction were frequent manifestations among AML patients which showed significantly higher serum creatinine, urea, ALT and AST levels compared with healthy individuals.Plasma β-catenin levels were significantly lower in AML patients, particularly in the M4/M5 subtypes characterized by monocytic differentiation. In contrast, no significant difference in β-catenin levels was observed between M0-M2 subtypes and controls. Age and FAB subtypes influenced β-catenin levels, with lower levels common in middle-aged patients (30–45 years) and the M5 subtype, while higher levels were associated with younger patients (18–30 years) and the M1 subtype.Expression of c-Myc mRNA did not differ significantly between overall AML patients and controls. However, subgroup analysis revealed substantially lower c-Myc expression in M4/M5 subtypes compared to M0-M2 subtypes and controls

Future Perspectives of Medical Pharmaceutical and Environmental BiotechnologyVol. 1(3)
Alexandria University (EG)
Openalex Percentile: Top 62%
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.